Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the Vabysmo (faricimab) marketing… read more.
Outlook Therapeutics, Inc., a biopharmaceutical company focused on the commercialization and development of ONs-5010/Lytenava (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, announced that the European Commission… read more.
Most people with early-stage glaucoma don’t know they have it, even though early treatment is key to reducing vision loss. While detecting a subtle increase in eye pressure… read more.
Eyenovia announced results from a Phase IV study of Mydcombi designed to characterize the lowest deliverable dose for mydriasis (pupil dilation). Mydcombi is the only FDA-approved fixed dose… read more.
Amgeny announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of… read more.
Dry Eye Disease (DED) is one of the more common eye diseases, affecting up to 30% of the world’s population. This disease can affect many different types of… read more.
NovaBay Pharmaceuticals, Inc. and Eyenovia, Inc. announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Under the agreement, NovaBay… read more.
The FDA has approved clobetasol propionate ophthalmic suspension 0.05% (APP 13007) by Taiwan-based Formosa Pharmaceuticals and AimMax Therapeutics. This suspension for the treatment of post-operative inflammation and pain… read more.
New research has shown a new type of inhibitor drug could prevent microvascular diabetic complications, such as diabetic eye and kidney disease. The University of Bristol-led research is… read more.
A new study suggests a naturally-occurring material is an effective disinfectant for contact lenses, worn by millions of people worldwide. Microbial keratitis is one of the most serious… read more.
Genentech, a member of the Roche Group announced new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo (faricimab-svoa) in macular edema due to… read more.
A new study has found there is significant scope to increase the number of eye donations from patients cared for in hospice and palliative care settings – donations… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
